The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Open accessAbstract
Bevacizumab, an antibody against vascular endothelial growth factor (VEGF), is a promising, yet controversial, drug in human glioblastoma treatment (GBM). Its effects on tumor burden, recurrence, and vascular physiology are unclear. We therefore determined the tumor response to bevacizumab at the phenotypic, physiological, and molecular level in a clinically relevant intracranial GBM xenograft model derived from patient tumor spheroids. Using anatomical and physiological magnetic resonance imaging (MRI), we show that bevacizumab causes a strong decrease in contrast enhancement while having only a marginal effect on tumor growth. Interestingly, dynamic contrast-enhanced MRI revealed a significant reduction of the vascular supply, as evidenced by a decrease in intratumoral blood flow and volume and, at the morphological level, by a strong reduction of large- and medium-sized blood vessels. Electron microscopy revealed fewer mitochondria in the treated tumor cells. Importantly, this was accompanied by a 68% increase in infiltrating tumor cells in the brain parenchyma. At the molecular level we observed an increase in lactate and alanine metabolites, together with an induction of hypoxia-inducible factor 1α and an activation of the phosphatidyl-inositol-3-kinase pathway. These data strongly suggest that vascular remodeling induced by anti-VEGF treatment leads to a more hypoxic tumor microenvironment. This favors a metabolic change in the tumor cells toward glycolysis, which leads to enhanced tumor cell invasion into the normal brain. The present work underlines the need to combine anti-angiogenic treatment in GBMs with drugs targeting specific signaling or metabolic pathways linked to the glycolytic phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“flow and oxygenation (normalization hypothesis) (1, 21, 36).”
BackgroundWhy Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B. W., Lee, T.-Y., Mayr, N. A., Parker, G. J. M., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s · Cited by 3,143
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Automatic quantitation of localized in vivo1H spectra with LCModel
Provencher, S. W. (2001) · NMR in Biomedicine · doi:10.1002/nbm.698 · Cited by 1,634
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., et al. (2010) · Nature · doi:10.1038/nature09557 · Cited by 1,379
Glioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., & Tabar, V. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,203
Anti-Angiogenesis: New Concept for Therapy of Solid Tumors
Folkman, J. (1972) · Annals of Surgery · doi:10.1097/00000658-197203000-00014 · Cited by 1,171
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Metabolic Modulation of Glioblastoma with Dichloroacetate
Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E., Maguire, C., Gammer, T.-L., Mackey, J. R., Fulton, D., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000677 · Cited by 720
Chenevert, T. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2029 · Cited by 673
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
Michelakis, E. D., Webster, L., & Mackey, J. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604554 · Cited by 656
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis
Robey, R. B., & Hay, N. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.010 · Cited by 540
Howe, F. A., Barton, S. J., Cudlip, S. A., Stubbs, M., Saunders, D. E., Murphy, M., Wilkins, P., Opstad, K. S., Doyle, V. L., McLean, M. A., et al. (2003) · Magnetic Resonance in Medicine · doi:10.1002/mrm.10367 · Cited by 539
Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, G. C., Judson, I. R., Knopp, M. V., Maxwell, R. J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602550 · Cited by 513
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker
Hylton, N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8080 · Cited by 410
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271
Ji, H., Wang, J., Nika, H., Hawke, D., Keezer, S., Ge, Q., Fang, B., Fang, X., Fang, D., Litchfield, D. W., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.034 · Cited by 270
Self-citationMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Pathania, D., Millard, M., & Neamati, N. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.010 · Cited by 263
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Antiangiogenic therapies for high-grade glioma
Norden, A. D., Drappatz, J., & Wen, P. Y. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.159 · Cited by 245
Lucio-Eterovic, A. K., Piao, Y., & de Groot, J. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0575 · Cited by 243
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
van den Bent, M. J., Vogelbaum, M. A., Wen, P. Y., Macdonald, D. R., & Chang, S. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4998 · Cited by 240
Angiogenesis-independent tumor growth mediated by stem-like cancer cells
Sakariassen, P. Ø., Prestegarden, L., Wang, J., Skaftnesmo, K.-O., Mahesparan, R., Molthoff, C., Sminia, P., Sundlisæter, E., Misra, A., Tysnes, B. B., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607668103 · Cited by 211
Self-citationConcerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Verhoeff, J. J., van Tellingen, O., Claes, A., Stalpers, L. J., van Linde, M. E., Richel, D. J., Leenders, W. P., & van Furth, W. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-444 · Cited by 189
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Norden, A. D., Drappatz, J., Muzikansky, A., David, K., Gerard, M., McNamara, M. B., Phan, P., Ross, A., Kesari, S., & Wen, P. Y. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9745-8 · Cited by 137
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wick, W., Weller, M., van den Bent, M. J., & Stupp, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9027 · Cited by 126
Beckner, M. E., Gobbel, G. T., Abounader, R., Burovic, F., Agostino, N. R., Laterra, J., & Pollack, I. F. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700355 · Cited by 115
A reproducible brain tumour model established from human glioblastoma biopsies
Wang, J., Miletić, H., Sakariassen, P. Ø., Huszthy, P. C., Jacobsen, H. K., Brekkå, N., Li, X., Zhao, P., Mørk, S. J., Chekenya, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-465 · Cited by 105
Self-citationAnti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms
Miletić, H., Niclou, S. P., Johansson, M., & Bjerkvig, R. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902806444 · Cited by 103
Self-citationGerstner, E. R., Frosch, M. P., & Batchelor, T. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0233 · Cited by 98
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
Reardon, D. A., Wen, P. Y., Desjardins, A., Batchelor, T. T., & Vredenburgh, J. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.541 · Cited by 88
Cancer stem cells and angiogenesis
Bjerkvig, R., Johansson, M., Miletić, H., & Niclou, S. P. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.09.001 · Cited by 56
Self-citationNestin expression in astrocytic tumors delineates tumor infiltration
Kitai, R., Horita, R., Sato, K., Yoshida, K., Arishima, H., Higashino, Y., Hashimoto, N., Takeuchi, H., Kubota, T., & Kikuta, K. (2010) · Brain Tumor Pathology · doi:10.1007/s10014-009-0261-0 · Cited by 55
Colin, C., Virard, I., Baeza, N., Tchoghandjian, A., Fernandez, C., Bouvier, C., Calisti, A., Tong, S., Durbec, P., & Figarella‐Branger, D. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00829.x · Cited by 43
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
On the Origin of Cancer Metastasis
Seyfried, T. N., & Huysentruyt, L. C. (2013) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.v18.i1-2.40 · Cited by 1,196
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Metadata
- Authors
- Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A. A., Fack, F., Thorsen, F., Taxt, T., Bartos, M., Jirik, R., Miletic, H., Wang, J., Stieber, D., Stuhr, L., Moen, I., Rygh, C. B., Bjerkvig, R., & Niclou, S. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-02-14
- Volume
- 108
- Issue
- 9
- Pages
- 3749-3754
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2101332957
- Cited by
- 606
- References
- 45
- FWCI
- 33.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.